The role of lamivudine in the treatment of HBe antigen negative liver cirrhosis | Zendy

Jasmina Simonovic-Babic | Zendy; Dragan Delić | Zendy; Neda Švirtlih | Zendy; Sladjana Pavić | Zendy; Nataša Popović | Zendy; Jasmina Poluga | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The role of lamivudine in the treatment of HBe antigen negative liver cirrhosis

Author(s) -

Jasmina Simonovic-Babic,

Dragan Delić,

Neda Švirtlih,

Sladjana Pavić,

Nataša Popović,

Jasmina Poluga

Publication year - 2006

Publication title -

medicinski pregled

Language(s) - English

Resource type - Journals

eISSN - 1820-7383

pISSN - 0025-8105

DOI - 10.2298/mpns0608317s

Subject(s) - medicine , lamivudine , cirrhosis , gastroenterology , hbeag , ascites , liver function , hbsag , hepatitis b , liver disease , decompensation , hepatitis b virus , interferon , hepatorenal syndrome , immunology , virus

Lamivudine is effective in suppressing hepatitis B virus replication and hepatic necroinflammatory activity. Patients with HBV-related chronic liver disease often present with hepatic decompensation and are not eligible for interferon therapy. The effectiveness of antiviral therapy in preventing disease progression in patients with hepatitis B cirrhosis is unknown. The aim of this study was to evaluate the effectiveness of lamivudine treatment in patients with cirrhosis due to chronic hepatitis B.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research